378 related articles for article (PubMed ID: 37071054)
1. Pharmacological management of youth with type 2 diabetes and diabetic kidney disease: a comprehensive review of current treatments and future directions.
Tommerdahl KL; Kula AJ; Bjornstad P
Expert Opin Pharmacother; 2023 Jun; 24(8):913-924. PubMed ID: 37071054
[TBL] [Abstract][Full Text] [Related]
2. Sodium-Glucose Cotransporter-2 Inhibitors-Miracle Drugs for the Treatment of Chronic Kidney Disease Irrespective of the Diabetes Status: Lessons from the Dedicated Kidney Disease-Focused CREDENCE and DAPA-CKD Trials.
Gohda T; Murakoshi M
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430228
[TBL] [Abstract][Full Text] [Related]
3. Novel therapeutic agents for the treatment of diabetic kidney disease.
Hartman RE; Rao PSS; Churchwell MD; Lewis SJ
Expert Opin Investig Drugs; 2020 Nov; 29(11):1277-1293. PubMed ID: 32799584
[TBL] [Abstract][Full Text] [Related]
4. Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease.
Kim DL; Lee SE; Kim NH
Endocrinol Metab (Seoul); 2023 Feb; 38(1):43-55. PubMed ID: 36891650
[TBL] [Abstract][Full Text] [Related]
5. Mineralocorticoid Antagonism and Diabetic Kidney Disease.
Lytvyn Y; Godoy LC; Scholtes RA; van Raalte DH; Cherney DZ
Curr Diab Rep; 2019 Jan; 19(1):4. PubMed ID: 30673886
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy for kidney disease in people with diabetes mellitus.
van Raalte DH; Bjornstad P; Cherney DZI; de Boer IH; Fioretto P; Gordin D; Persson F; Rosas SE; Rossing P; Schaub JA; Tuttle K; Waikar SS; Heerspink HJL
Nat Rev Nephrol; 2024 Jul; 20(7):433-446. PubMed ID: 38570632
[TBL] [Abstract][Full Text] [Related]
7. Present and future directions in diabetic kidney disease.
Limonte CP; Kretzler M; Pennathur S; Pop-Busui R; de Boer IH
J Diabetes Complications; 2022 Dec; 36(12):108357. PubMed ID: 36403478
[TBL] [Abstract][Full Text] [Related]
8. Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets.
Barrera-Chimal J; Jaisser F
Diabetes Obes Metab; 2020 Apr; 22 Suppl 1():16-31. PubMed ID: 32267077
[TBL] [Abstract][Full Text] [Related]
9. Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists.
Winiarska A; Knysak M; Nabrdalik K; Gumprecht J; Stompór T
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639160
[TBL] [Abstract][Full Text] [Related]
10. The potential for improved outcomes in the prevention and therapy of diabetic kidney disease through 'stacking' of drugs from different classes.
Bell DSH; Jerkins T
Diabetes Obes Metab; 2024 Jun; 26(6):2046-2053. PubMed ID: 38516874
[TBL] [Abstract][Full Text] [Related]
11. Youth versus adult-onset type 2 diabetic kidney disease: Insights into currently known structural differences and the potential underlying mechanisms.
Tommerdahl KL; Kendrick J; Nelson RG; Bjornstad P
Clin Sci (Lond); 2022 Nov; 136(21):1471-1483. PubMed ID: 36326718
[TBL] [Abstract][Full Text] [Related]
12. A Narrative Review of Diabetic Kidney Disease: Previous and Current Evidence-Based Therapeutic Approaches.
Mima A
Adv Ther; 2022 Aug; 39(8):3488-3500. PubMed ID: 35751762
[TBL] [Abstract][Full Text] [Related]
13. Recent Advances in the Management of Diabetic Kidney Disease: Slowing Progression.
Wang N; Zhang C
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542060
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in the pharmacotherapeutic management of diabetic kidney disease.
Block TJ; Batu D; Cooper ME
Expert Opin Pharmacother; 2022 May; 23(7):791-803. PubMed ID: 35522659
[TBL] [Abstract][Full Text] [Related]
15. Advancements in diabetic kidney disease management: integrating innovative therapies and targeted drug development.
Ghose S; Satariano M; Korada S; Cahill T; Shah R; Raina R
Am J Physiol Endocrinol Metab; 2024 Jun; 326(6):E791-E806. PubMed ID: 38630049
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.
Lerma E; White WB; Bakris G
Postgrad Med; 2023 Apr; 135(3):224-233. PubMed ID: 35392754
[TBL] [Abstract][Full Text] [Related]
17. New progress in drugs treatment of diabetic kidney disease.
Wang J; Xiang H; Lu Y; Wu T; Ji G
Biomed Pharmacother; 2021 Sep; 141():111918. PubMed ID: 34328095
[TBL] [Abstract][Full Text] [Related]
18. SGLT2 Inhibitors and Other Novel Therapeutics in the Management of Diabetic Kidney Disease.
Stanton RC
Semin Nephrol; 2021 Mar; 41(2):85-95. PubMed ID: 34140099
[TBL] [Abstract][Full Text] [Related]
19. Ion homeostasis in diabetic kidney disease.
Hu H; Liang W; Ding G
Trends Endocrinol Metab; 2024 Feb; 35(2):142-150. PubMed ID: 37880052
[TBL] [Abstract][Full Text] [Related]
20. Renal effects of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment.
Weir MR
Postgrad Med; 2019 Aug; 131(6):367-375. PubMed ID: 31132013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
